loader2
Partner With Us NRI

Piramal Pharma Ltd share Price Today

Company details

123.20
129.40
61.62
149.00
6M Return 33.09%
1Y Return 103.22%
Mkt Cap.(Cr) 17,052.80
Volume 5,924,097
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 5,924,097

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Piramal Pharma announced Q3FY24 & 9MFY24 results:

  • Revenue from Operations grew by 14% YoY both in Q3FY24 and 9MFY24, driven by double-digit growth across all the three businesses
    • Q3FY24: Rs 1,959 crore (14% YoY growth)
    • 9MFY24: Rs 5,619 crore (14% YoY growth)
  • EBITDA grew by 94% YoY and 71% YoY in Q3FY24 and 9MFY24 respectively, primarily driven by operating leverage, reduction in raw material cost & energy prices, cost optimization, and operational excellence initiatives
    • Q3FY24: Rs 330 crore (94% YoY growth)
    • 9MFY24: Rs 815 crore (71% YoY growth)
  • Net Debt / EBITDA ratio has improved over the last three quarters on account of healthy growth in EBITDA and repayment of debt from the proceeds of the recently concluded Rights Issue
  • Sustainability - Taken a target to reduce Scope 1 and Scope 2 emissions by 42% by FY30 (with a baseline of FY22), which is in accordance with the 1.5 degrees C trajectory suggested by SBTi. Further, we have also taken a target to reduce Scope 3 emissions by 25% by FY30 (with a baseline of FY22)

Nandini Piramal, Chairperson, Piramal Pharma said, “We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation-related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of the US and is also seeing increasing traction in ROW markets. Our India Consumer Healthcare business is delivering steady growth driven by our power brands and contributions from new product launches.

On the sustainability front, we have taken significant reduction targets for our Scope 1, 2, and 3 GHG emissions by FY2030. We are also working on multiple initiatives in the areas of water conservation, responsible waste disposal, gender diversity, employee safety, sustainable supply chain, and community development.

We look forward to continuing our momentum in Q4 and ending the financial year on a positive note.”

 

Result PDF

View Other Company Results

Piramal Pharma Ltd shares SWOT Analysis

Strengths (6)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Increasing Revenue every quarter for the past 2 quarters
  • Increasing profits every quarter for the past 2 quarters

Weakness (5)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • Stock with Low PE (PE < = 10)

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 131.1
R2 133.4
R3 137.3
Pivot

127.17

S1 124.9
S2 121.0
S3 118.7
EMA SMA
124.6
128.5
126.1
119.4
124.1
132.5
130.6
114.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
EAST BRIDGE CAPITAL MASTER FUND I LIMITED Bulk Purchase 2023-10-31 102.8 33643099 BSE
EAST BRIDGE CAPITAL MASTER FUND LIMITED Bulk Sell 2023-10-31 102.8 33643099 BSE
EAST BRIDGE CAPITAL MASTER FUND I LIMITED Block Purchase 2023-10-31 102.8 33643099 BSE
Name Category Shares
The Sri Krishna Trust through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A Piramal PROMOTER 26.67%
V3 Designs LLP PROMOTER 3.25%
PRL Realtors LLP PROMOTER 3.01%
Piramal Welfare Trust (Formerly known as The Piramal Enterprise Executives Trust) PROMOTER 0.8%
AASAN Corporate Solutions Pvt. Ltd PROMOTER 0.68%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Piramal Pharma Ltd Stocks COMPARISON

Financials( in Cr) Piramal Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 128.90 1,620.55 1,496.95 6,157.90 1,007.35
% Change 5.35 1.02 2.30 1.88 0.77
Mcap Cr 17,052.80 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 7,081.55 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr -186.46 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 0.00 41.13 29.93 19.30 30.34
1 Year Return 103.22 64.78 68.33 37.28 109.04
ROCE 1.90 16.79 14.76 25.99 16.25
ROE -2.77 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 6,773.50 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 30,755.54 35,765.55
LAST 3M 69,913.40 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,259.39 209,046.49

Piramal Pharma Ltd Information

Stock PE (TTM)
0
Promoter Holding
35.02%
Book Value
58.6407
ROCE
1.9%
ROE
-2.77%
Description
  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paid-up equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ bio-therapeutics and vaccine segments. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little`s, Tetmosol, i-Pill and Polycrol. Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Company`s global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions. In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL). In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA). In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL was effective from August 18, 2022. In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited `NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.

Registered Address

Ground Floor Piramal Ananta, Agastya Corp.Park LBS MargKurl, Mumbai, Maharashtra, 400070

Tel : 91-22-3802-3000/4000
Email : corporate.secretarial:piramal.com
Website : http://www.piramalpharma.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543635
NSE Code : PPLPHARMA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE0DK501011

FAQ’s on Piramal Pharma Ltd Shares

You can buy Piramal Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Piramal Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:57 PM the closing price of Piramal Pharma Ltd was ₹ 128.90.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:57 PM, the market cap of Piramal Pharma Ltd stood at ₹ 17,052.80.

The latest PE ratio of Piramal Pharma Ltd as of Mar 28, 2024 03:57 PM is 0

The latest PB ratio of Piramal Pharma Ltd as of Mar 28, 2024 03:57 PM is 0.48

The 52-week high of Piramal Pharma Ltd share price is ₹ 149.00 while the 52-week low is ₹ 61.62

Download Our

Download App
market app